PKM Monoclonal Antibody

Code CSB-MA018072A0m
Size US$350
Image
  • Western Blot
    Positive WB detected in: Hela whole cell lysate, MCF-7 whole cell lysate, Jurkat whole cell lysate, NIH/3T3 whole cell lysate
    All lanes: PKM antibody at 1:4000
    Secondary
    Goat polyclonal to Mouse IgG at 1/10000 dilution
    Predicted band size: 58 kDa
    Observed band size: 58 KDa
    Exposure time: 1min

     

  • Western Blot
    Positive WB detected in: Mouse Heart tissue, Mouse Brain tissue, Mouse Skeletal Muscle tissue
    All lanes: PKM antibody at 1:4000
    Secondary
    Goat polyclonal to Mouse IgG at 1/10000 dilution
    Predicted band size: 58 kDa
    Observed band size: 58 KDa

  • Western Blot
    Positive WB detected in: Rat Heart tissue, Rat Spleen tissue, Rat Brain tissue
    All lanes: PKM antibody at 1:4000
    Secondary
    Goat polyclonal to Mouse IgG at 1/10000 dilution
    Predicted band size: 55-60 kDa
    Observed band size: 55-60 kDa

  • Western Blot
    Positive WB detected in: MCF-7 whole cell lysate at 40µg, 20µg, 10µg, 5µg, 2.5µg, 1.25µg, 0.625µg, 0.3125µg
    All lanes: PKM antibody at 1:4000
    Secondary
    Goat polyclonal to Mouse IgG at 1/10000 dilution
    Predicted band size: 58 kDa
    Observed band size: 58 KDa
    Exposure time: 5min

  • Western Blot
    Positive WB detected in: MCF-7 whole cell lysate
    All lanes: PKM antibody at 1:4000, 1:8000, 1:16000, 1:32000, 1:64000, 1:128000, 1:256000
    Secondary
    Goat polyclonal to Mouse IgG at 1/10000 dilution
    Predicted band size: 58 kDa
    Observed band size: 58 KDa
    Exposure time: 5min

  • IHC image of CSB-MA018072A0m diluted at 1:400 and staining in paraffin-embedded human tonsil tissue performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4°C overnight. The primary is detected by a biotinylated secondary antibody and visualized using an HRP conjugated SP system.

  • IHC image of CSB-MA018072A0m diluted at 1:400 and staining in paraffin-embedded human tonsil tissue performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4°C overnight. The primary is detected by a biotinylated secondary antibody and visualized using an HRP conjugated SP system.

  • IHC image of CSB-MA018072A0m diluted at 1:400 and staining in paraffin-embedded human tonsil tissue performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4°C overnight. The primary is detected by a biotinylated secondary antibody and visualized using an HRP conjugated SP system.

  • IHC image of CSB-MA018072A0m diluted at 1:400 and staining in paraffin-embedded human lung cancer tissue performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4°C overnight. The primary is detected by a biotinylated secondary antibody and visualized using an HRP conjugated SP system.

  • IHC image of CSB-MA018072A0m diluted at 1:400 and staining in paraffin-embedded human lung cancer tissue performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4°C overnight. The primary is detected by a biotinylated secondary antibody and visualized using an HRP conjugated SP system.

  • IHC image of CSB-MA018072A0m diluted at 1:400 and staining in paraffin-embedded human lung cancer tissue performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4°C overnight. The primary is detected by a biotinylated secondary antibody and visualized using an HRP conjugated SP system.

  • IHC image of CSB-MA018072A0m diluted at 1:400 and staining in paraffin-embedded human kidney tissue performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4°C overnight. The primary is detected by a biotinylated secondary antibody and visualized using an HRP conjugated SP system.

  • IHC image of CSB-MA018072A0m diluted at 1:400 and staining in paraffin-embedded human kidney tissue performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4°C overnight. The primary is detected by a biotinylated secondary antibody and visualized using an HRP conjugated SP system.

  • IHC image of CSB-MA018072A0m diluted at 1:400 and staining in paraffin-embedded human kidney tissue performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4°C overnight. The primary is detected by a biotinylated secondary antibody and visualized using an HRP conjugated SP system.

  • Immunofluorescence staining of A549 cells with CSB-MA018072A0m at 1:230, counter-stained with DAPI. The cells were blocked in 10% normal Goat Serum and then incubated with the primary antibody overnight at 4°C. The secondary antibody was Alexa Fluor 488-congugated AffiniPure Goat Anti-Mouse IgG(H+L).

  • Immunofluorescence staining of Hela cells with CSB-MA018072A0m at 1:230, counter-stained with DAPI. The cells were blocked in 10% normal Goat Serum and then incubated with the primary antibody overnight at 4°C. The secondary antibody was Alexa Fluor 488-congugated AffiniPure Goat Anti-Mouse IgG(H+L).

  • Immunofluorescence staining of HepG2 cells with CSB-MA018072A0m at 1:230, counter-stained with DAPI. The cells were blocked in 10% normal Goat Serum and then incubated with the primary antibody overnight at 4°C. The secondary antibody was Alexa Fluor 488-congugated AffiniPure Goat Anti-Mouse IgG(H+L).

  • Immunoprecipitating PKM in Hela whole cell lysate
    Lane 1: Mouse control IgG instead of CSB-MA018072A0m in Hela whole cell lysate.
    Lane 2: CSB-MA018072A0m (1?l) + Hela whole cell lysate (500?g)
    Lane 3: Hela whole cell lysate (10?g)
    For western blotting, the blot was detected with CSB-MA018072A0m at 1:2000, and a HRP-conjugated Protein G antibody was used as the secondary antibody at 1:2000

  • Overlay histogram showing Hela cells stained with CSB-MA018072A0m (red line) at 1:100. The cells were incubated in 1x PBS /10% normal goat serum to block non-specific protein-protein interactions followed by primary antibody for 1 h at 4°C. The secondary antibody used was FITC goat anti-mouse IgG(H+L) at 1/200 dilution for 1 h at 4°C. Isotype control antibody (green line) was used under the same conditions. Acquisition of >10,000 events was performed.

  • Overlay histogram showing HepG2 cells stained with CSB-MA018072A0m (red line) at 1:100. The cells were incubated in 1x PBS /10% normal goat serum to block non-specific protein-protein interactions followed by primary antibody for 1 h at 4°C. The secondary antibody used was FITC goat anti-mouse IgG(H+L) at 1/200 dilution for 1 h at 4°C. Isotype control antibody (green line) was used under the same conditions. Acquisition of >10,000 events was performed.

Have Questions? Leave a Message or Start an on-line Chat

Product Details

Full Product Name Mouse anti-Homo sapiens (Human) PKM Monoclonal antibody
Uniprot No. P14618
Target Names PKM
Alternative Names CTHBP antibody; Cytosolic thyroid hormone-binding protein antibody; KPYM_HUMAN antibody; OIP-3 antibody; Opa-interacting protein 3 antibody; p58 antibody; pkm antibody; PKM1 antibody; PKM2 antibody; Pyruvate kinase 2/3 antibody; Pyruvate kinase muscle isozyme antibody; Pyruvate kinase PKM antibody; THBP1 antibody; Thyroid hormone-binding protein 1 antibody; Tumor M2-PK antibody
Raised in Mouse
Species Reactivity Human, Rat, Mouse, Rabbit
Immunogen Recombinant Human Pyruvate kinase PKM protein (2-531AA)
Immunogen Species Homo sapiens (Human)
Conjugate Non-conjugated
Clonality Monoclonal
Isotype IgG1
Clone No. 6C3C7
Purification Method >95%, Protein G purified
Concentration It differs from different batches. Please contact us to confirm it.
Buffer Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, PH 7.4
Form Liquid
Tested Applications ELISA, WB, IHC, IF, FC, IP
Recommended Dilution
Application Recommended Dilution
WB 1:4000-1:256000
IHC 1:200-1:500
IF 1:150-1:300
FC 1:50-1:200
IP 1µl-4µl
Protocols ELISA Protocol
Western Blotting(WB) Protocol
Immunohistochemistry (IHC) Protocol
Immunofluorescence (IF) Protocol
Flow Cytometry (FC) Protocol
Immunoprecipitation (IP) Protocol
Troubleshooting and FAQs Antibody FAQs
Storage Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Lead Time Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

Target Data

Function Glycolytic enzyme that catalyzes the transfer of a phosphoryl group from phosphoenolpyruvate (PEP) to ADP, generating ATP. Stimulates POU5F1-mediated transcriptional activation. Plays a general role in caspase independent cell death of tumor cells. The ratio between the highly active tetrameric form and nearly inactive dimeric form determines whether glucose carbons are channeled to biosynthetic processes or used for glycolytic ATP production. The transition between the 2 forms contributes to the control of glycolysis and is important for tumor cell proliferation and survival.
Gene References into Functions
  1. results reveal that nBP1a/PKM2 interaction activates lipid metabolism genes in cancer cells and that Thr-59 phosphorylation of SREBP-1a plays an important role in cancer cell proliferation. PMID: 29514980
  2. we demonstrated that knockdown of PKM2 can inhibit GC cell proliferation, G1-S phase transition, can, especially, attenuate GC cell migration in vivo and in vitro, per contra, promote the autophagy, which may depend on mediating the PI3K-Akt signaling. PMID: 28588255
  3. PKM1 activated glucose catabolism and stimulated autophagy/mitophagy, favoring malignancy PMID: 29533781
  4. miRNA-139-5p inhibited cell proliferation, migration, and glycolysis in GBC, at least in part, by repressing pyruvate kinase M2 PMID: 30105813
  5. Mammalian target of rapamycin pathway promotes aerobic glycolysis in esophageal squamous cell carcinoma by upregulating pyruvate kinase M2 isoform PMID: 29916308
  6. PKM2 promotes tumor cell exosome release via phosphorylating protein SNAP23. PMID: 28067230
  7. proteins such as MMP2 and MMP9 as well as P38 expression were also affected by the PKM2 expression changes. These results proved that PKM2 could be involved in the progression of bladder cancer by mitogen-activated protein kinases signaling pathway. PMID: 30249877
  8. hypoxic stress in the hepatocellular carcinoma (HCC)cells promoted YAP binding to HIF-1a in the nucleus and sustained HIF-1a protein stability to bind to PKM2 gene and directly activates PKM2 transcription to accelerate glycolysis PMID: 30180863
  9. overexpressed PKM2 led to increased CCND1 and decreased CDKN1A expression, whereas underexpressed PKM2 led to decreased CCND1 and increased CDKN1A expression in ovarian cancer cells. PMID: 29752805
  10. Our current study thus unveils a distinct regulatory function of PKM2, providing new options for therapeutic intervention targeting HIV-1-host interactions. PMID: 29607934
  11. PKM2 as a novel target of RUNX1-ETO and is specifically downregulated in RUNX1-ETO positive AML patients, indicating that PKM2 level might have a diagnostic potential in RUNX1-ETO associated AML. PMID: 28092997
  12. High M2-PK expression is associated with pancreatic cancer and peri-ampullary cancer. PMID: 29540198
  13. The activity of PKM2 was indispensable for the development and metastasis of OS. PMID: 29155364
  14. fFndings demonstrate that mDC activation requires an elevated intrinsic PKM2 level and that PKM2 improves the immune status of patients with SAA by enhancing the functions of mDCs and, consequently, CTLs. PMID: 29636835
  15. EGFR activation results in c-Src-mediated Cdc25A phosphorylation at Y59, which interacts with nuclear pyruvate kinase M2 (PKM2). PMID: 27485204
  16. Study demonstrate that PKM2 plays an important role in metabolic activities, as well as in the malignancy of pancreatic ductal adenocarcinoma cells. PMID: 29393401
  17. Suggest a critical role for pyruvate kinase isozyme M2 in mediating the interaction between pancreatic cancer cells and pancreatic stellate cells. PMID: 29619774
  18. Results show that PK2 expression level is regulated by HSP90 in hepatocellular carcinoma (HCC). HSP90 enhances PKM2 stability by inducing the phosphorylation of PKM2 at Thr-328. PMID: 29262861
  19. O-GlcNAcylation is a regulatory mechanism for PKM2 in cancer cells and serves as a bridge between PKM2 and metabolic reprogramming typical of the Warburg effect. PMID: 29229835
  20. Results indicate that PKM2 is positively correlated with Sp1 expression and demonstrate that Sp1 directly regulates its expression in castration-resistant prostate cancer. PMID: 29094170
  21. High PKM2 expression is associated with lung adenocarcinoma. PMID: 28489603
  22. Epigenetic silencing of miR-338 facilitates glioblastoma progression by preventing suppression the PKM2/beta-catenin axis. PMID: 28858851
  23. this study correlates TuM2PK with tumor size, CRP and CA 15-3 in metastatic breast carcinomas. PMID: 28869444
  24. PKM2 modulates the glycolysis and extracellular matrix generation, providing the vital role of PKM2 on osteoarthritis (OA) pathogenesis and a novel therapeutic target for OA. PMID: 29356574
  25. This work suggested that OA increased PKM1/PKM2 ratio, resulting in HNF-4alpha activation and hepatoma differentiation. PMID: 28726775
  26. the present findings enriched our knowledge by demonstrating a significant association of PKM2 and GLS1 with oxaliplatin-resistance in CRC. PMID: 28498807
  27. Elevated expression of PKM2 is a prognostic factor for poor gallbladder cancer (GBC) clinical outcomes, implied involving of PKM2 in GBC progression. PMID: 27283076
  28. PKM2 knockdown resulted in increased p53 expression and prolonged half-life of p53. PKM2 could directly bind with both p53 and MDM2 and promote MDM2-mediated p53 ubiquitination. The dimeric PKM2 significantly suppressed p53 expression compared with the other PKM2 mutants. PMID: 27801666
  29. Inhibition of the mTOR pathway abolished TGF-beta1-induced EMT and reduced mTOR/p70s6k signaling, which downregulated PKM2 expression. PMID: 28446743
  30. Study indicates that nitric oxide induces PKM2 nuclear translocation and promotes glycolysis in ovarian cancer cells. PMID: 28380434
  31. Authors report that AKT directly interacts with PKM2 and phosphorylates it at Ser-202, which is essential for the nuclear translocation of PKM2 protein under stimulation of IGF-1. In the nucleus, PKM2 binds to STAT5A and induces IGF-1-stimulated cyclin D1 expression, suggesting that PKM2 acts as an important factor inducing STAT5A activation under IGF-1 signaling. PMID: 27340866
  32. The results suggested that targeting PKM2 with an oncolytic adenovirus produced a strong antitumor effect. PMID: 28569774
  33. our results demonstrated that miR-let-7a inhibits cell proliferation, migration and invasion by down-regulation of PKM2 in cervical cancer PMID: 28415668
  34. Data show that cytomegalovirus encoded chemokine receptor US28 (US28) signaling in activation of the HIF-1alpha/PKM2 feedforward loop in fibroblasts and glioblastoma cells. PMID: 27602585
  35. High PKM2 expression is associated urothelial tumorigenesis. PMID: 26992222
  36. Report that PKM2 is succinylated at lysine 498 and succinylation increases its activity. SIRT5 binds to, desuccinylates and inhibits PKM2 activity. Increased levels of reactive oxygen species (ROS) decreases succinylation and activity of PKM2 by increasing its binding to SIRT5. PMID: 28036303
  37. over-expression of PKM2 is associated with poor prognosis in most solid cancers and it might be a potentially useful biomarker for predicting cancer prognosis in future clinical applications. PMID: 27911861
  38. Interdependence of GLO I and PKM2 in the Metabolic shift to escape apoptosis in GLO I-dependent cancer cells PMID: 29225125
  39. This study demonstrates that lapachol inhibits glycolysis in cancer cells by targeting PKM2. Unlike the previously reported inhibitor shikonin, lapachol does not target mitochondria in tumor cell growth inhibition. PMID: 29394289
  40. In this study, we indicate that P53 (N340Q/L344R) promotes hepatocarcinogenesis through upregulation of PKM2 PMID: 27167190
  41. These findings indicate that shRNA-mediated silencing of PKM2 gene promotes apoptosis and inhibits aerobic glycolysis, proliferation, migration, and invasion in colorectal cancer cells. PMID: 28543190
  42. Due to achieved results concerning expression of PKM2 there is a lack of evidence for its diagnostic and prognostic usage in ovarian cancer. PMID: 29277786
  43. UCP2 stimulates hnRNPA2/B1, GLUT1 and PKM2 expression and sensitizes pancreatic cancer cells to glycolysis inhibition. PMID: 27989750
  44. These findings uncover a novel mechanism through which mitochondrial PKM2 phosphorylates Bcl2 and inhibits apoptosis directly. PMID: 28035139
  45. These findings suggested that PKM2 and GLS might play important roles in the proliferation of hypoxic gastric cancer cells PMID: 29032577
  46. demonstrated that lincRNA-p21 blunted the prostate cancer cell proliferation and tumorigenic capacity through down-regulation of PKM2 PMID: 28994148
  47. we demonstrated that SHP-1 dephosphorylates PKM2Y105 to inhibit the Warburg effect and nucleus-dependent cell proliferation, and the dephosphorylation of PKM2Y105 by SHP-1 determines the efficacy of targeted drugs for hepatocellular carcinoma treatment PMID: 26959741
  48. The PKM2-shRNA group exhibited reduced PKM2 mRNA and protein expression, whereas p53 and p21 expression was increased compared with the blank and empty plasmid groups. PMID: 28746922
  49. The CARM1-PKM2 axis serves as a metabolic reprogramming mechanism in tumorigenesis. PMID: 29058718
  50. PKM2 activity is higher in patients with NSCLC than in healthy subjects. The level of PKM2 activity is associated with advanced stage of cancer. PMID: 27683215
  51. reverse phase protein microarrays identified the glycolysis promoting PKM2 and IF1 proteins as specific biomarkers of dermatomyositis. PMID: 28183315
  52. It has been found that the adaptor protein receptor for activated PKC kinase (RACK1) formed a complex with FGFR1 and PKM2, and activated the FGFR1/PKM2 signaling. The study shows that RACK1 forms a complex with FGFR1 and PKM2, and stimulates the growth and migration of squamous lung cancer cells. PMID: 28418088
  53. These results suggest that increased expression of PKM2 is not required to support c-MYC-induced tumorigenesis in the liver and that various PKM1/PKM2 ratios and pyruvate kinase activities can sustain glucose catabolism required for this process. PMID: 28630053
  54. The PKM2 may promote hepatic IR via STAT3 pathway and would provide a new insight into dissecting the molecular pathogenesis of hepatic insulin resistance. PMID: 28802581
  55. Data suggest that PKM1 and PKM2, alternative splice variants that interact with each other, are expressed and localized differently in lung carcinoma cell lines; PKM1 or PKM2 knockdown (via RNA interference) differentially affects net pyruvate kinase activity, mitochondrial biogenesis, energy metabolism, ATP level, autophagy, and apoptosis/cell viability. PMID: 28778925
  56. Study reveals a mechanism that the Warburg effect is regulated by CHIP through its function as an E3 ligase, which mediates the degradation of PKM2 during tumor progression. PMID: 28346425
  57. Data show that pyruvate kinase M2 (PKM2) directly interacted with mutant growth factor receptor (EGFR) and heat-shock protein 90 (HSP90), and thus stabilized EGFR by maintaining its binding with HSP90 and co-chaperones. PMID: 26500058
  58. Knockdown of PKM2 in GC cells caused significant decreases in cellular proliferation. PMID: 28235245
  59. In the glomeruli of patients with longstanding diabetes with and without diabetic nephropathy, pyruvate kinase M2 (PKM2) expression and activity were upregulated. PKM2 activation may protect against DN by increasing glucose metabolic flux, inhibiting the production of toxic glucose metabolites and inducing mitochondrial biogenesis to restore mitochondrial function. PMID: 28436957
  60. Studied interactions of polypyrimidine tract-binding protein (PTBP1), pyruvate kinase M2 (PKM2), and STAT3 (signal transducer and activator of transcription 3) in oncogenesis of anaplastic large cell lymphoma (ALCL). Results show that in ALCL cells, PTBP1 is crucial for PKM2 phosphorylation of STAT3 in the nucleus. PMID: 28414323
  61. We further hypothesize that mTOR/PKM2 pathway stimulation serves to sustain the oncogenic activity of mutant p53 through both the enhancement of chemoresistance and of aerobic glycolysis of cancer cells PMID: 27385486
  62. Acetylation of PKM2 is associated with breast Cancer. PMID: 27197174
  63. Blockage of autophagy enhanced Tat-induced HIV-1 transactivation in TZM-bl cells. Moreover, Tat activated the Akt/mTOR and inhibited AMPK signaling pathway that was related to its up-regulation of PKM2 expression. PMID: 28583828
  64. PKM2 downregulation resulted in, metformin inhibited glucose uptake, lactate production and ATP production in osteosarcoma cancer stem cells PMID: 28393220
  65. High PKM2 expression is associated with clear-cell renal cell carcinoma. PMID: 27431728
  66. our results identified that mammalian sterile 20-like kinase 1 is a novel downstream target of pyruvate kinase M2, and knockdown of pyruvate kinase M2 contributes apoptosis via promoting nuclear translocation of mammalian sterile 20-like kinase 1 by enhancing Caspase-3-dependent cleavage. PMID: 28656802
  67. RBM4 is induced and is involved in the PKM splicing switch and neuronal gene expression during hypoxia-induced neuronal differentiation. PMID: 27821480
  68. Overexpression of miR-133b inhibited the growth and proliferation of lung cancer stem cells by down regulating PKM2. PMID: 28641694
  69. Jmjd8 is upregulated during endothelial differentiation and regulates endothelial sprouting and metabolism by interacting with pyruvate kinase M2. PMID: 27199445
  70. Authors subsequently investigated whether miR-4417 and TRIM35 regulate HCC cell proliferation and apoptosis through PKM2 Y105 phosphorylation, and the results supported our speculation that miR-4417 targets TRIM35 and regulates the Y105 phosphorylation of PKM2 to promote hepatocarcinogenesis. PMID: 28394882
  71. In CRC, sensitivity of M2PK, iFOBT, and Hb/Hp complex proved to be high. Combined use of M2PK, iFOBT, and FC may be valuable in the detection of large adenomas. PMID: 27413251
  72. PKM2 interferes with phosphorylation of P53 at serine 15, known to stimulate P53 activity by the ATM serine/threonine kinase. PMID: 27810895
  73. PKM2 is a transcriptional co-activator of HIV-1 long terminal repeat. PMID: 27249540
  74. These findings suggest that 3,3',5-triiodothyroxine (T3) can inhibit apoptosis and oxidative stress in an oxygen-glucose deprivation/reperfusion model AC16 and HCM-a cells by regulating the PKM2/PKM1 ratio. PMID: 27163637
  75. results show that the Aha1-Hsp90-PKM2/HIF-1alpha axis mediates the induction of aromatase in Li-Fraumeni Syndrome. PMID: 27467582
  76. the anticancer activity of tanshinone A was targeted at metabolic regulation of miR-122/PKM2 in human esophagus cancer cells. PMID: 27040384
  77. Study shows that the enhanced expression of PKM2 in lung cancer cells is likely associated with the biological properties of cancer stem cells. PMID: 28259998
  78. Overexpression of PKM2 and LDH5 associates with key clinicopathological features and unfavourable prognosis in tongue squamous cell carcinoma. PMID: 24762230
  79. we revealed a novel mechanism of pyruvate kinase M2 in promoting colorectal cancer progression by recruitment of macrophages through p65 nuclear factor-kappaB-mediated expression of CCL2. PMID: 28347237
  80. Results show that PKM2 physically associates with TSC22D2 reducing its nuclear localization and contributing to tumor suppressor function of TSC22D2 in colorectal cancer. PMID: 27573352
  81. Cell migration and invasion were significantly suppressed by siRNA-PKM2. PMID: 28281967
  82. PKM2 expression was elevated in the cancerous tissues and it was more abundant than the adjacent normal tissues. the overall survival for patients with high PKM2 expression was significantly lower than those with low PKM2 expression. PMID: 27644251
  83. Nuclear PKM2 expression as an independent risk factor for early recurrence of hepatocellular carcinoma after curative resection. PMID: 27894667
  84. Increased PKM2 expression is associated with triple-negative breast cancer. PMID: 26715276
  85. Critical roles of PKM2 in the stemness of breast cancer cells which may elevate the therapeutic effect on breast cancer patients. PMID: 26493994
  86. PKM2 was involved in progression of ESCC. PMID: 26404132
  87. PKM2 knockdown leaded to increased radiosensitivity of radioresistant cell lines. Significant inhibition in tumor size under regular radiotherapy was found in Balb/c-nude mice bearing radioresistant NSCLC tumors with PKM2 knockdown. PMID: 25649613
  88. Faecal tumor M2-pyruvate kinase ELISA may have utility as an adjunct to faecal occult blood test in a screening context, but do not support its use in symptomatic patients. PMID: 27014756
  89. PKM2 interacts with Tristetraprolin directly, regulates Tristetraprolin transcriptional modification, destabilizes Tristetraprolin, and then impairs cell proliferation in breast cancer. Collectively, the results offer evidence of a role for PKM2 in Tristetraprolin regulation in cancer cells which may be a potential therapy target in breast cancer. PMID: 26926077
  90. our studies reveal the prognostic value of PKM2 in colorectal cancer PMID: 26617865
  91. Our results provided the first phosphorylome of PKM2 and revealed a constitutive mTORC1 activating mechanism in cancer cells. PMID: 26876154
  92. PKM2/TG2 interplay plays an important role in the regulation of autophagy in particular under cellular stressful conditions such as those displayed by cancer cells. PMID: 26702927
  93. GLUT3 and OCT4 expression were correlated suggesting that Human embryonic stem cells self-renewal is regulated by the rate of glucose uptake. PMID: 26639784
  94. PKM2 can regulate cell motility through the EGF/EGFR and TGFbeta/TGFR signaling pathways in hepatocellular carcinoma cells. PMID: 26290635
  95. High PKM2 expression significantly correlated with poor response to chemotherapy in Esophageal Squamous Cell Carcinoma. PMID: 25808097
  96. The activation of STAT3 by nuclear PKM2 was associated with gefitinib resistance. PMID: 26542452
  97. PKM1 has a role in resistance to anti-cancer drugs PMID: 27012213
  98. High PKM2 expression is associated with colorectal cancer. PMID: 26506517
  99. Loss of PKM2 expression was associated with Pancreatic Ductal Adenocarcinoma. PMID: 26385349
  100. findings point to PKM2 and PTBP1 as new potential therapeutic targets to improve response of PDAC to chemotherapy PMID: 26234680

Show More

Hide All

Subcellular Location Cytoplasm, Nucleus
Protein Families Pyruvate kinase family
Tissue Specificity Specifically expressed in proliferating cells, such as embryonic stem cells, embryonic carcinoma cells, as well as cancer cells.
Database Links

HGNC: 9021

OMIM: 179050

KEGG: hsa:5315

STRING: 9606.ENSP00000320171

UniGene: Hs.534770

Most popular with customers

Newsletters

Get all the latest information on Events, Sales and Offers. Sign up for newsletter today.

© 2007-2020 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1